large1 Antibody

What is LARGE1 and what is its primary function in cellular biology?

LARGE1 (like-glycosyltransferase) is a member of the N-acetylglucosaminyltransferase gene family that functions as a glycosyltransferase primarily in the Golgi apparatus. It plays a crucial role in the post-translational modification of alpha-dystroglycan (α-DG) by adding xylose and glucuronic acid to form matriglycan, which enables α-DG to bind extracellular matrix ligands including laminin 211 and neurexin . The protein encoded by LARGE1 is essential for proper muscle function, as mutations in this gene cause several forms of congenital muscular dystrophy characterized by cognitive disability and abnormal glycosylation of alpha-dystroglycan .

What experimental applications are LARGE1 antibodies suitable for?

LARGE1 antibodies have been validated for several research applications:

When selecting an antibody for these applications, researchers should consider the species reactivity (human and mouse are most commonly available) and the specific epitope recognized .

How should LARGE1 antibodies be stored and handled for optimal performance?

For optimal performance of LARGE1 antibodies, follow these storage recommendations:

• For continuous use, store undiluted antibody at 2-8°C for up to one week

• For long-term storage, aliquot and store at -20°C or below to prevent degradation from repeated freeze/thaw cycles

• Avoid storage in frost-free freezers due to temperature fluctuations

• Gently spin the vial prior to opening and mix the antibody solution before use

• Buffer conditions typically include PBS with preservatives like sodium azide (typically 15 mM)

• Working concentration ranges from 0.1-5 μg/ml depending on the application and specific antibody

Proper handling ensures antibody stability and consistent experimental results over time.

How is LARGE1 expression detected in tissue samples?

Detection of LARGE1 in tissue samples involves several complementary approaches:

In immunohistochemistry or immunofluorescence studies, LARGE1 immunoreactivity is typically measured using standardized microscopy settings (laser intensity, exposure time, contrast) to ensure consistency . Image analysis software like ImageJ can be used to quantify signal intensity, with normalization against background signals for each tissue section .

When analyzing LARGE1 levels across different samples (e.g., comparing disease vs. normal tissue), relative protein levels are calculated by normalizing the intensity against control tissue or against housekeeping proteins . For example, in studies of spinal muscular atrophy (SMA), LARGE1 immunoreactivity in the ventral horn or SMI-32 positive spinal motor neurons is measured and compared between SMA tissue and wild-type tissue .

How do LARGE1, POMK, and α-DGN interact in matriglycan synthesis?

The synthesis of matriglycan on α-DG involves a sophisticated interplay between LARGE1, protein O-mannose kinase (POMK), and the N-terminal domain of dystroglycan (α-DGN). Research has revealed that:

• LARGE1 requires both phosphorylated core M3 (modified by POMK) and interaction with α-DGN to extend matriglycan to its full mature length

• In the absence of either POMK or α-DGN, LARGE1 can only synthesize a shorter form of matriglycan

• Solution NMR studies show that phosphorylated core M3 (GGMp-MU) binds to LARGE1 with greater affinity compared to the unphosphorylated form (GGM-MU)

• The interaction between LARGE1 and α-DGN appears to stabilize the enzyme-substrate complex over multiple cycles of sugar addition, enabling efficient elongation of matriglycan chains

When both components are present, LARGE1 synthesizes full-length matriglycan (resulting in α-DG of ~150-250 kDa), which is necessary to prevent muscle pathophysiology . This mechanism explains why mutations in any of these components can lead to similar muscular dystrophy phenotypes.

What methodologies are most effective for studying LARGE1's role in muscle pathophysiology?

To study LARGE1's role in muscle pathophysiology, researchers employ several complementary approaches:

In vitro systems:

• Cell lines with naturally occurring LARGE1 deficiency (e.g., Rh18 cells from embryonal rhabdomyosarcoma)

• CRISPR/Cas9-mediated knockout of LARGE1 in relevant cell lines

• Viral vector-mediated overexpression of LARGE1 to restore glycosylation

In vivo models:

• The myodystrophy (myd) mouse model carrying a spontaneous deletion in LARGE1

• Conditional knockout models to control temporal aspects of LARGE1 deletion

• Skeletal muscle-specific α-DGN deletion models

Functional assessments:

• Laminin overlay assays to evaluate α-DG binding capacity

• Force production measurements before and after eccentric contractions

• Respiratory function tests measuring tidal volume and minute volume

• Locomotor activity tracking and grip strength measurements

Molecular analyses:

• Western blotting with IIH6 antibody to detect matriglycan

• Quantitative solid-phase laminin binding assays

• Histological evaluation of muscle architecture and fibrosis

• Immunofluorescence to analyze neuromuscular junction morphology

Therapeutic approaches:

• AAV-mediated gene transfer of LARGE1 in mouse models with established disease

• Metabolomic profiling of plasma to identify biomarkers of treatment response

This multi-faceted approach allows researchers to connect molecular mechanisms to physiological outcomes and potential therapeutic interventions.

How can researchers differentiate between functional variations in LARGE1-mediated glycosylation?

Differentiating between functional variations in LARGE1-mediated glycosylation requires sophisticated analytical techniques:

Western blotting with glycosylation-specific antibodies:

• IIH6 antibody recognizes the laminin-binding epitope on matriglycan

• Changes in molecular weight of α-DG can indicate differences in glycosylation extent

• Fully glycosylated α-DG appears at ~150-250 kDa, while reduced glycosylation results in ~100-125 kDa forms

Advanced mass analysis techniques:

• Mass photometry (MP) provides sensitive characterization of glycosylated species with better resolution for heterogeneously glycosylated proteins compared to native mass spectrometry

• Single-particle charge detection mass spectrometry (CD-MS) can accurately measure masses of heterogeneous assemblies

• Size exclusion chromatography multi-angle light scattering (SEC-MALS) remains an established method but offers lower resolution

Functional binding assays:

• Solid-phase laminin binding assays can quantify the functional consequences of altered glycosylation

• Binding affinity measurements correlate with matriglycan chain length

Researchers should select techniques based on the specific glycosylation aspects being investigated.

What strategies can improve antibody specificity for LARGE1 versus LARGE2?

Distinguishing between LARGE1 and its paralog LARGE2 presents a significant challenge in antibody-based research. Strategies to address this include:

Epitope selection:

• Target unique regions that differ between LARGE1 and LARGE2

• The recombinant fragment corresponding to amino acids 35-142 of human LARGE1 has been successfully used as an immunogen

• Antibodies raised against this region show specificity for LARGE1

Validation approaches:

• Test antibody reactivity in cells with CRISPR-knockout of either LARGE1 or LARGE2

• Perform competitive binding assays with recombinant LARGE1 and LARGE2 proteins

• Validate antibody specificity through immunoprecipitation followed by mass spectrometry

Application-specific considerations:

• For Western blotting, utilize the slight molecular weight differences between LARGE1 (~209 kDa) and LARGE2

• For immunofluorescence, co-staining with Golgi markers (e.g., GM130) can help confirm specificity based on subcellular localization

• For flow cytometry, inclusion of isotype controls and blocking experiments is essential

Many commercial antibodies (like LARGE-02) explicitly state that cross-reactivity with LARGE2 has not been determined , highlighting the need for independent validation by researchers.

How does LARGE1 gene transfer restore function in muscular dystrophy models?

LARGE1 gene transfer has demonstrated remarkable therapeutic potential in muscular dystrophy models, working through several mechanisms:

Molecular restoration:

• AAV-mediated LARGE1 expression restores matriglycan on α-DG

• This reestablishes the critical link between the cytoskeleton and extracellular matrix

• LARGE1 overexpression can even generate hyperglycosylated α-DG with enhanced laminin-binding capacity

Functional improvements:

• Systemic AAV-LARGE1 treatment in adult myd mice significantly improves:

  • Locomotor activity and rearing behavior

  • Forelimb grip strength

  • Respiratory muscle function (increased tidal volume and minute volume)

  • Body weight maintenance

  • Survival (extending lifespan significantly even in mice with advanced disease)

Histological benefits:

• Reduction in fibrous tissue infiltration

• Restoration of normal muscle architecture

• Improvement in neuromuscular junction morphology

Metabolic normalization:

• Plasma metabolomic profiling shows normalization of systemic metabolism following LARGE1 gene therapy

• This suggests broader physiological benefits beyond direct muscle effects

Remarkably, LARGE1 gene transfer shows efficacy even when initiated in older animals with established disease, with treated mice showing significantly improved survival (>65 weeks) compared to untreated controls (50% mortality by 45 weeks) . This demonstrates the therapeutic potential of targeting LARGE1 in muscular dystrophies even after disease onset.

How can LARGE1 antibodies be used to investigate altered glycosylation in cancer?

LARGE1 antibodies have proven valuable for investigating altered glycosylation in cancer, particularly in rhabdomyosarcoma (RMS) and other cancers where abnormal α-DG glycosylation may contribute to disease progression:

Expression analysis:

• Western blotting with LARGE1 antibodies has revealed downregulation of LARGE1 specifically in embryonal rhabdomyosarcoma (ERMS) cells and biopsy samples

• This downregulation correlates with loss of functional α-DG glycosylation

Functional consequences:

• Reduced LARGE1 expression results in nearly complete loss of matriglycan modification on α-DG

• This leads to impaired laminin binding and potentially altered tumor cell-matrix interactions

Therapeutic implications:

• Ectopic expression of recombinant LARGE1 in LARGE1-deficient cancer cells (e.g., Rh18 cells) restores:

  • Matriglycan modification of α-DG to levels similar to those in normal muscle-derived cells

  • High-affinity laminin-binding function

This research suggests that LARGE1 deficiency may represent a mechanism through which cancer cells alter their interactions with the extracellular matrix, potentially affecting invasiveness and metastatic potential. LARGE1 antibodies provide a valuable tool for identifying such alterations in patient samples and evaluating potential therapeutic strategies targeting glycosylation pathways.

What are the best methods for validating LARGE1 antibody specificity?

Validating LARGE1 antibody specificity requires a multi-faceted approach to ensure reliable experimental results:

Controls for Western blotting:

• Positive controls: Cell lines with known LARGE1 expression (e.g., wild-type HAP1 cells)

• Negative controls: LARGE1 knockout cell lines generated via CRISPR/Cas9

• Size verification: LARGE1 should appear at approximately 209-250 kDa

• Multiple antibodies: Use antibodies targeting different epitopes of LARGE1 for confirmation

Immunoprecipitation validation:

• IP followed by Western blotting with a different LARGE1 antibody

• Mass spectrometry analysis of immunoprecipitated proteins to confirm identity

• Competition assays with immunizing peptide to demonstrate specificity

Tissue expression patterns:

• Compare antibody staining with known LARGE1 mRNA expression patterns

• Ensure appropriate subcellular localization (primarily Golgi apparatus)

• Include isotype control antibodies to identify non-specific binding

Functional validation:

• Correlate LARGE1 detection with functional glycosylation of α-DG (using IIH6 antibody)

• Test antibody reactivity following LARGE1 siRNA knockdown

• Verify antibody performance in LARGE1 overexpression systems

For quantitative studies, establish standard curves with recombinant LARGE1 protein to ensure linearity of detection across relevant concentration ranges.

How do advanced biophysical techniques complement antibody-based detection of LARGE1-modified glycoproteins?

Advanced biophysical techniques provide critical complementary data to antibody-based detection when studying LARGE1-modified glycoproteins:

Comparative strengths of different techniques:

When analyzing heavily glycosylated antibody-antigen assemblies like IgG:sEGFR complexes, mass photometry (MP) outperforms native mass spectrometry by providing reliable measurements of average masses for all co-occurring complexes . This advantage is particularly important when studying LARGE1-modified α-DG, which exhibits significant glycosylation heterogeneity.

For megadalton assemblies involving complement activation complexes with highly glycosylated components, both MP and charge detection mass spectrometry (CD-MS) offer advantages over traditional techniques . These methods can help characterize the functional consequences of LARGE1 activity by providing accurate mass measurements of the resulting glycoprotein complexes.

These biophysical approaches should be used alongside antibody-based detection to provide comprehensive characterization of LARGE1-modified glycoproteins and their interaction partners.

What considerations are important when designing experiments to study LARGE1 in neuromuscular junction pathology?

When designing experiments to study LARGE1's role in neuromuscular junction (NMJ) pathology, researchers should consider several key factors:

Model selection:

• α-DGN-deleted mouse models show NMJ abnormalities despite maintaining specific force, making them valuable for studying LARGE1's role in NMJ formation and maintenance

• Conditional knockout systems allow temporal control of LARGE1 deletion to distinguish developmental versus maintenance roles

Visualization techniques:

• Fluorescent α-bungarotoxin staining for acetylcholine receptors coupled with presynaptic markers

• Quantitative analysis of NMJ morphology (size, fragmentation, innervation)

• Super-resolution microscopy for detailed structural analysis

Functional assessments:

• Electrophysiological recording of neuromuscular transmission

• Force measurements before and after eccentric contractions to assess NMJ stability under stress

• Assessment of muscle fatigue characteristics

Molecular analysis:

• Evaluation of matriglycan levels specifically at the NMJ using IIH6 antibody

• Analysis of LARGE1 localization relative to NMJ components

• Investigation of interactions between LARGE1-modified α-DG and NMJ-specific ligands

Therapeutic approaches:

• AAV-mediated LARGE1 gene transfer with NMJ-focused outcome measures

• Timing considerations: intervention before versus after NMJ abnormalities develop

Studies have demonstrated that while a shortened form of matriglycan (produced in the absence of α-DGN) can maintain specific force, it fails to prevent NMJ abnormalities , highlighting the importance of full-length matriglycan for proper NMJ structure and function.

How can computational modeling enhance understanding of LARGE1 antibody specificity?

Computational modeling approaches are emerging as powerful tools to enhance antibody specificity, including for targets like LARGE1:

Current computational approaches:

• Biophysics-informed modeling combined with selection experiments can disentangle different binding modes associated with particular ligands

• These models can identify antibody sequences with customized specificity profiles, either targeting specific ligands or exhibiting cross-specificity

• Energy function optimization can be employed to design novel antibody sequences with predefined binding profiles

Application to LARGE1 antibody development:

• Computational models could predict antibody sequences that specifically recognize LARGE1 over LARGE2

• Energy minimization approaches could optimize binding to unique epitopes on LARGE1

• Models can be trained using phage display experiments with various combinations of related targets

Validation and implementation:

• Experimental validation through testing computationally predicted variants is essential

• Complementary approaches like random forest classification (AbRFC) have been successful in discovering affinity-enhancing mutations

• Integration of computational prediction with experimental screening has shown >1000-fold improved affinity in real-world applications

Advancing these computational approaches could lead to next-generation LARGE1 antibodies with enhanced specificity and binding characteristics for research and potential diagnostic applications.

What is the potential of LARGE1 as a biomarker in neuromuscular disorders?

Recent research suggests LARGE1 has significant potential as a biomarker in neuromuscular disorders:

Evidence from spinal muscular atrophy (SMA) studies:

• Proteomic-based discovery studies on cerebrospinal fluid (CSF) identified LARGE1 as a protein increased in SMA patients compared to controls

• This increase was observed both before and during nusinersen treatment

• LARGE1 levels can be measured in both CSF and serum samples using enzyme-linked immunosorbent assay (ELISA)

Methodological approaches:

• Immunofluorescence analysis of spinal cord and skeletal muscle tissue from murine SMA models

• Standardized microscopy settings and image analysis protocols for consistent quantification

• Normalization of LARGE1 immunoreactivity against appropriate controls

Clinical applications:

• Serum measurements offer potential for minimally invasive monitoring

• Studies include pre-symptomatic as well as type 1, 2, and 3 SMA patients

• Potential utility for treatment monitoring, as LARGE1 levels remain altered during treatment

Future directions:

• Correlation of LARGE1 levels with disease progression and treatment response

• Investigation of LARGE1 as a biomarker in other neuromuscular disorders

• Development of standardized assays for clinical implementation

Further research is needed to fully establish the sensitivity, specificity, and predictive value of LARGE1 as a biomarker across different neuromuscular conditions and treatment contexts.